3月21日 - ** 药物开发商Arvinas（ARVN.O）股价下跌3.4%，至8.70美元
** 经纪公司Leerink将PT从49美元下调至12美元，维持“跑赢大盘”评级
** 尽管vepdegestrant的初步结果令人失望，但Leerink认为，在详细数据发布和一系列关键价值杠杆的可见性得到确认之前，应坚持既定路线并保持业绩领先
** Vepdegestrant、ARVN和辉瑞的PFE.N口服药物在上周的晚期试验中未能延缓 (link) 乳腺癌患者病情的发展，而该疾病是最常见类型的乳腺癌
** 现在断言维普德格不如依拉雌醇还为时过早，因为意向治疗人群的失败可能是由多种因素导致的——经纪
** 依拉雌醇用于治疗某些类型的激素受体阳性乳腺癌
** 截至上次收盘，ARVN年初至今下跌53
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.